Biological function of fusion protein ATF-PAI2CD

Acta Biochimica et Biophysica Sinica

Volumn 35, Issue 7, 2003, Pages 624-628

  Wang, Xia ^a   Li, Ping ^a   Zhang, Yu Qing ^a   Hou, Min ^a   Sun, Xing Hui ^a   Tan, Li ^a   Zhu, Yun Song ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Expression; Fusion protein; Purification; Radio ligand receptor binding assay

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENTARY DNA; DNA FRAGMENT; HYBRID PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 2; RADIOLIGAND; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UROKINASE TYPE PLASMINOGEN ACTIVATOR AMINO TERMINAL FRAGMENT PLASMINOGEN ACTIVATOR INHIBITOR TYPE 2;

ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; EXPRESSION VECTOR; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; LUNG CANCER; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SOLUBILIZATION; TEMPERATURE; WESTERN BLOTTING; WILD TYPE;

ESCHERICHIA COLI; HUMANS; LUNG NEOPLASMS; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECOMBINANT FUSION PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; VECTORS;

EID: 0042071206     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Magdolen V et al. The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinolysis, 2000, 14 (2/3): 114-132
2. Foekens JA, Buessecker F, Peters HA, Krainick U, Van Putten WL, Look MP, Klijn JG et al. Plasminogen activator inhibitor-2: Prognostic relevance in 1012 patients with primary breast cancer. Cancer Res, 1995, 55 (7): 1423-1427
3. Tian Y, Shen JQ, Li P, Zhu YS. The protection function of the PAI-2 from TNF-α is dependent upon its protein binding domain. Acta Biochim Biophys Sin, 2000, 32 (2): 175-178
4. Jensen PH, Jensen TG, Laug WE, Hager H, Gliemann J, Pepinsky B. The exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain. J Biol Chem, 1996, 271 (43): 26892-26899
5. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci, 2000, 57 (1): 25-40
6. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs, 2001, 12 (5): 387-400
7. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer, 1997, 72 (1): 1-22
8. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989
9. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EK. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res, 1993, 53 (24): 6051-6057
10. Wang JY, Jia HY, Song HY. Determination of the activity of tissue-type plasminogen activator and its inhibitor in human plasma. Chin J Med Lab Sci, 1989, 12 (3): 163
11. Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR et al. A hybrid protein of urokinase growth-factor domain and plasminogen activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem, 1992, 207 (1): 177-183
12. Feng XL. Refolding of recombinant inclusion body proteins. Prog Biochem Biophys, 2001, 28 (4): 482-485
13. Tian Y, Shen JQ, Li P, Song HY, Zhu YS. Expression and purification of human plasminogen activator inhibitor type 2 in E.coli. Chin J Biochem Mol Biol, 1998, 14 (5): 536-541
14. Tian Y, Shen JQ, Li P, Zhu YS. Biochemical characterization of PAI-2 and its mutants. Acta Biochim Biophys Sin, 2000, 32 (2): 126-132
15. Webb DJ, Nguyen DHD, Sankovic M, Gonias SL. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J Biol Chem, 1999, 274 (11): 7412-7420
16. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the 2-macroglobulin receptor. J Biol Chem, 2000, 275 (11): 7566-7573
17. Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci, 2001, 114 (18): 3387-3396